Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Jun. 30, 2011
REVENUES	$ 571	$ 889	$ 2,795	$ 4,612
COST OF SALES	1,149	1,102	2,841	6,315
GROSS MARGIN	(578)	(213)	(46)	(1,703)
Research and development	12,386	107,523	60,746	146,113
Depreciation and amortization	168	308	526	958
Bad debt expense			203
General and administrative	60,591	394,257	573,042	1,148,572
Total Operating Expenses	73,145	502,088	634,517	1,295,643
OPERATING LOSS	(73,723)	(502,301)	(634,563)	(1,297,346)
Patent licensing income		133,725		133,725
Loss on equity investment		(8,358)		(8,358)
Other income		(7)	3,124	603
Total Other Income (Expense)		125,360	3,124	125,970
Loss before income taxes and noncontrolling interest	(73,723)	(376,941)	(631,439)	(1,171,376)
NET LOSS	(73,723)	(376,941)	(631,439)	(1,171,376)
Less: Net loss attributable to noncontrolling interest	(16,350)	(13,166)	(52,027)	(45,433)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(57,373)	(363,775)	(579,412)	(1,125,943)
Foreign currency translation adjustments	(18,924)	(12,262)	28,207	43,865
Total Other Comprehensive Income (Loss)	(18,924)	(12,262)	28,207	43,865
COMPREHENSIVE LOSS	$ (92,647)	$ (389,203)	$ (603,232)	$ (1,127,511)
BASIC AND DILUTED LOSS PER SHARE	$ 0.00	$ 0.00	$ (0.01)	$ (0.01)
BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	118,742,272	97,035,545	115,492,406	88,869,853